| P2093 | author name string | Ray Y Hachem | |
| | Ying Jiang | |
| | Issam Raad | |
| | Anne-Marie Chaftari | |
| | Fady Ghaly | |
| | Rita Wilson Dib | |
| P2860 | cites work | Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. | Q51617424 |
| | Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria be revised? | Q53552170 |
| | The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study | Q80050239 |
| | Galactomannan detection for invasive aspergillosis in immunocompromised patients | Q24186895 |
| | Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia | Q26778187 |
| | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| | Triazole Resistance in Aspergillus Species: An Emerging Problem | Q30235566 |
| | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America | Q34532546 |
| | Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. | Q35528678 |
| | Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles | Q35584615 |
| | Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis | Q35789251 |
| | Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach | Q35794490 |
| | Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity | Q35867884 |
| | Serum galactomannan levels in the diagnosis of invasive aspergillosis | Q36272128 |
| | Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 |
| | Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial | Q38103680 |
| | Update on antifungal resistance in Aspergillus and Candida. | Q38174185 |
| | Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study | Q40331138 |
| | Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study | Q40376327 |
| | Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. | Q40395042 |
| | An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality | Q40399765 |
| | The current management landscape: aspergillosis | Q40438379 |
| | Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study | Q40497134 |
| | Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia | Q40847963 |
| | Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies | Q41629771 |
| | Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization | Q41653776 |
| | The role of antifungal treatment in hematology | Q42615864 |
| | Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign | Q44023091 |
| | Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. | Q44059632 |
| | Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay | Q46503389 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | invasive aspergillosis | Q3625278 |
| | infectious disease | Q18123741 |
| | diagnosis | Q16644043 |
| P304 | page(s) | 656 | |
| P577 | publication date | 2018-12-13 | |
| P1433 | published in | BMC Infectious Diseases | Q15759919 |
| P1476 | title | Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies | |
| P478 | volume | 18 | |